Placenta cell therapy shows promise for tough transplant complication

NCT ID NCT04118556

Terminated Disease control Sponsor: Mats Remberger Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tested a treatment made from placenta cells (called decidua stroma cells) in 12 adults who had severe graft-versus-host disease (GVHD) after a stem cell transplant and did not respond to steroids. Patients received two doses of the cells or the best available standard therapy. The goal was to see if the cell treatment was safe and could improve outcomes by day 56.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: placenta-derived decidua stroma cells (DSC)
What this could lead to: If it works, this could offer a new treatment option for patients with severe graft-versus-host disease that does not respond to steroids.
What could go wrong: This is a small, early-phase trial (only 12 patients) that was terminated, so results are limited. The treatment may not work better than existing options and carries risks like infection or infusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GVHD, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GVHD, ACUTE

Contacts and locations

Locations

Copenhagen Univerity Hospital

Copenhagen, 2300, Denmark
Lund University Hospital

Lund, SE-221 85, Sweden
Oslo University Hospital

Oslo, NO-0424, Norway
Uppsala University Hospital

Uppsala, SE-75185, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.